PT-141

Description

PT-141

Overview: PT-141 is the research name for bremelanotide, a synthetic peptide and melanocortin receptor agonist investigated for its effects on sexual function. It was approved by the U.S. FDA in 2019 under the brand name VYLEESI® for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

How It Works

Bremelanotide acts centrally on melanocortin receptors in the brain—especially the MC4R receptor subtype—to influence pathways that regulate sexual desire and arousal.

Onset of Action

Effects generally begin within ~45 minutes of administration, with peak concentrations around 1 hour. Both desired effects and side effects typically occur shortly after dosing and are usually transient.

Reported Side Effects

• Nausea (most common; sometimes severe enough to require antiemetics).
• Flushing and headache.
• Injection-site reactions.
• Temporary increases in blood pressure with mild decreases in heart rate.

Research Use Only: PT-141 is offered strictly for laboratory and research purposes. It is not approved for human consumption, medical, or veterinary use.